These are the people that should be kicked out. Trying to project and scare people with second guessing. The data and clinical trials for Jak Inhibitors safety profile.
This is not an educated answer.
The summary for Vitiligo through clinical trials is this:
Why You See Warnings for Cancer and Infection
Even though the vitiligo trial data is highly reassuring, regulatory bodies like the FDA and EMA still require upadacitinib to carry prominent warnings for serious infections, malignancies (cancer), and blood clots.
This is because these risks are recognized as a class effect of Janus kinase (JAK) inhibitors. The broader class warnings are primarily based on long-term data from older, higher-risk patients who took JAK inhibitors for rheumatoid arthritis, rather than the younger, generally healthier population typically enrolled in vitiligo trials.
Also reported in the clinical trials:
Serious Risks & Notable Absence in Trials
• Serious Infections: Occasional reports of localized or systemic infections (such as bronchitis or localized complications) that generally resolve without requiring drug discontinuation.
**• Major Adverse Events**: Phase 3 48-week evaluations reported no cases of active tuberculosis, opportunistic infections outside of herpes zoster, major adverse cardiovascular events (MACE), venous thromboembolic events (VTE), or gastrointestinal perforations.